Professor Ulf Klein
- Position: Professor of Immunology and Haemato-oncology
- Areas of expertise: Immunology; B lymphocytes; B cells; germinal centre; memory B cells; plasma cells; transcription factors; mechanisms of cancer development; lymphomagenesis; gene expression profiling; flow cytometry
- Email: U.P.Klein@leeds.ac.uk
- Location: Level 6 Room 6.19a Wellcome Trust Brenner Building
- Website: LinkedIn | Googlescholar | Researchgate | ORCID
I graduated from the University of Cologne in 1993 with a diploma in biology, which included a year abroad at King’s College London where I studied biochemistry (non-award).
I completed my PhD, in which I specialized in immunology, at the University of Cologne in 1998.
I moved to Columbia University, New York City, for my postdoctoral research, supported by EMBO and HFSP fellowships. I stayed at Columbia as an Associate Research Scientist from 2003.
In 2009, I accepted an offer from Columbia University to establish my independent research group as Assistant Professor of Pathology & Cell Biology and Microbiology & Immunology. I was promoted to Associate Professor with tenure in 2016.
In January 2017, I was appointed as Professor in Immunology and Haemato-oncology at the University of Leeds, where I lead the Molecular Haematology group in the Leeds Institute of Medical Research (LIMR) at St. James's.
- Head of the Molecular Haematology Group
The goal of my research group is to understand the oncogenic mechanisms that cause malignant transformation of mature B cells and plasma cells.
Cancers of the B-cell lineage, lymphomas and multiple myeloma, can be very aggressive, and often the cancer rapidly reoccurs after standard therapy. Thus, there is a clinical need for more effective therapies against these malignancies, which requires a better understanding of the biology of these cancers.
My laboratory focusses on the elucidation of the molecular mechanisms that govern the differentiation of B cells. We aim to understand how the disruption of these mechanisms by genetic mutations leads to the development of B-cell and plasma cell malignancies.
The research is expected to identify Achilles’ heels in the tumour cells that are vulnerable for intervention with anti-cancer drugs. This is a prerequisite for the realization of precision medicine in the treatment of haematological malignancies.
- PhD in Genetics
- Diploma in Biology
- American Society of Hematology
- American Association of Immunologists
- British Society for Immunology
- German Society for Immunology (DGfI)
I teach students in the MSc Molecular Medicine course and I supervise PhD students.
Research groups and institutes
- Leeds Institute of Medical Research at St James's